Develops innovative treatments for mental health disorders, leveraging a combination of psychedelic and non-psychedelic compounds.
Atai Life Sciences N.V., operating through its subsidiary ATAI Life Sciences AG, is a clinical-stage biopharmaceutical company dedicated to developing therapeutic candidates targeting various mental health disorders. The company's robust pipeline includes innovative treatments such as PCN-101, a subcutaneous formulation of R-ketamine aimed at addressing treatment-resistant depression (TRD). Additionally, it is advancing RL-007, a modulator of cholinergic, glutamatergic, and GABA-B receptors designed to treat cognitive impairment associated with schizophrenia.
Among its other promising candidates are DMX-1002, an oral formulation of ibogaine targeting opioid use disorder (OUD), and GRX-917, an oral version of deuterated etifoxine for generalized anxiety disorder. Atai Life Sciences N.V. is also developing NN-101, an intranasal formulation of N-acetylcysteine for mild traumatic brain injuries, and VLS-01, a formulation of N,N-dimethyltryptamine for TRD treatment.
Founded in 2018 and headquartered in Berlin, Germany, Atai Life Sciences N.V. was previously known as Adripa Holding B.V. The company's commitment to advancing novel therapies underscores its mission to address unmet needs in mental health, collaborating with healthcare professionals to redefine treatment possibilities for patients worldwide.